Åsa Wallin
11 – 20 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
(
- Contribution to journal › Article
-
Mark
Early- versus Late-Onset Alzheimer’s Disease—Differences in Functional Impairment.
2016) 9th Clinical Trials Conference on Alzheimer’s Disease(
- Contribution to conference › Poster
- 2015
-
Mark
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
(
- Contribution to journal › Article
-
Mark
DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts.
(
- Contribution to journal › Article
-
Mark
The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey.
(
- Contribution to journal › Article
-
Mark
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
(
- Contribution to journal › Article
- 2014
-
Mark
Early- versus Late-onset Alzheimer’s Disease—3-year Outcomes of Cholinesterase Inhibitor Treatment in Routine Clinical Practice.
2014) 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster
- 2013
-
Mark
Mild versus Moderate Stage of Alzheimer’s Disease—Three-year Outcomes of Cholinesterase Inhibitor Therapy in a Routine Clinical Setting.
(
- Contribution to conference › Abstract
-
Mark
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
(
- Contribution to journal › Article
-
Mark
Living Alone in Alzheimer’s Disease—The Influence of Functional Impairment.
2013) 6th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster